Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 10

Results For "HAE"

171 News Found

Harbor Healthcare advises a California long-term care pharmacy on its sale & strategic partnership
News | January 04, 2023

Harbor Healthcare advises a California long-term care pharmacy on its sale & strategic partnership

The strategic acquirer maintains a nationwide presence in the LTC pharmacy space


Takeda launches CINRYZE in India for hereditary angioedema patients
News | December 15, 2022

Takeda launches CINRYZE in India for hereditary angioedema patients

CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.


PM lays foundation stone for National Institute for One Health in Nagpur
Policy | December 12, 2022

PM lays foundation stone for National Institute for One Health in Nagpur

The Institute will focus on increasing preparedness and laboratory capabilities for identification of novel and unknown zoonotic agents


BASF and MedAccess complete shipment of 35 million interceptor G2 nets to fight malaria
Healthcare | December 09, 2022

BASF and MedAccess complete shipment of 35 million interceptor G2 nets to fight malaria

35 million mosquito nets supplied to countries in sub-Saharan Africa through partners


Healthium divests its UK based continence care organization Clinisupplies
News | December 07, 2022

Healthium divests its UK based continence care organization Clinisupplies

Proceeds from the transaction will be reinvested towards the growth, innovation and expansion of Healthium’s advanced surgery, orthopaedics, wound care and post-surgical care portfolio


Panacea Biotec bags US $127.30 mn for supply of Pentavalent Vaccine
Biotech | October 11, 2022

Panacea Biotec bags US $127.30 mn for supply of Pentavalent Vaccine

UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027


Yingli Pharma announces first patient dosed in Phase 2 Trial of Linperlisib for peripheral T Cell Lymphoma
Diagnostic Center | September 05, 2022

Yingli Pharma announces first patient dosed in Phase 2 Trial of Linperlisib for peripheral T Cell Lymphoma

Phase 2 study to assess efficacy and safety of once daily linperlisib in patients with advanced peripheral T/NK cell lymphoma


PharmaCyte Biotech reaches cooperation agreement with Iroquois Capital
Biotech | August 16, 2022

PharmaCyte Biotech reaches cooperation agreement with Iroquois Capital

Company appoints five new independent directors to reconstituted board


AstraZeneca completes acquisition of TeneoTwo
News | August 13, 2022

AstraZeneca completes acquisition of TeneoTwo

AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.